## Core Concept
Eculizumab is a monoclonal antibody that targets and inhibits the complement protein C5, a key component of the complement system. The complement system is part of the innate immune system and plays a crucial role in the body's defense against pathogens. However, its dysregulation can lead to various diseases. Eculizumab's mechanism of action involves preventing the formation of the membrane attack complex (MAC) and the pro-inflammatory mediators C5a.

## Why the Correct Answer is Right
The correct answer, **Paroxysmal Nocturnal Hemoglobinuria (PNH)**, is a rare, acquired, life-threatening disease of the blood characterized by the destruction of red blood cells (hemolysis), bone marrow failure, and the presence of blood clots. Eculizumab has been specifically approved for the treatment of PNH because it effectively reduces intravascular hemolysis, improves anemia, and decreases the risk of blood clot formation by inhibiting the complement-mediated destruction of red blood cells.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because, although **Myasthenia Gravis (MG)** is an autoimmune disease, eculizumab is not primarily used for its treatment. MG is characterized by weakness and rapid fatigue of the muscles under voluntary control. While there are various treatments for MG, including immunosuppressive drugs and acetylcholinesterase inhibitors, eculizumab's specific mechanism does not primarily target the neuromuscular junction pathology seen in MG.
- **Option B:** This option is incorrect because **Multiple Sclerosis (MS)** is a chronic autoimmune disease that affects the central nervous system. The treatments for MS primarily involve disease-modifying therapies that target the immune system in a broader sense, not specifically the complement C5 component.
- **Option C:** This option is incorrect because **Rheumatoid Arthritis (RA)** is an autoimmune disorder that primarily affects joints. While RA involves immune dysregulation, eculizumab's targeted mechanism against C5 is not the standard approach for treating RA.

## Clinical Pearl / High-Yield Fact
A key point to remember is that eculizumab increases the risk of infections, particularly those caused by Neisseria species, due to its complement inhibitory effects. Therefore, patients on eculizumab should be vaccinated against Neisseria meningitidis before starting treatment.

## Correct Answer Line
**Correct Answer: D. Paroxysmal Nocturnal Hemoglobinuria (PNH).**